4-Benzyloxy-2-imidazol-1-yl-7-methoxy-quinoline | 300830-96-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-Benzyloxy-2-imidazol-1-yl-7-methoxy-quinoline
• 英文别名: 2-imidazol-1-yl-7-methoxy-4-phenylmethoxyquinoline
• CAS: 300830-96-0
• 化学式: C₂₀H₁₇N₃O₂
• 分子量: 331.374
• InChiKey: YHUXPBGSXUKQGD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-Benzyloxy-2-imidazol-1-yl-7-methoxy-quinoline 在 palladium on activated charcoal 偶氮二甲酸二异丙酯 、 氢气 、 三苯基膦 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 生成 (Z)-(1S,4R,6S,14S,18R)-14-tert-Butoxycarbonylamino-18-(2-imidazol-1-yl-7-methoxy-quinolin-4-yloxy)-2,15-dioxo-3,16-diaza-tricyclo[14.3.0.0^4,6]nonadec-7-ene-4-carboxylic acid methyl ester
  参考文献：
  名称：

  Structure−Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061

  摘要：

  From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified. Structure-activity relationship studies were per-formed focusing on optimizing the N-terminal carbamate and the aromatic substituent on the (4R)-hydroxyproline moiety. Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified. BILN 2061 was selected as the best compound, the first NS3 protease inhibitor reported with antiviral activity in man.

  DOI：

  10.1021/jm0342414
• 作为产物：
  描述：

  咪唑 、 4-benzyloxy-2-(chloro)-7-methoxyquinoline 生成 4-Benzyloxy-2-imidazol-1-yl-7-methoxy-quinoline
  参考文献：
  名称：

  Structure−Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061

  摘要：

  From the discovery of competitive hexapeptide inhibitors, potent and selective HCV NS3 protease macrocyclic inhibitors have been identified. Structure-activity relationship studies were per-formed focusing on optimizing the N-terminal carbamate and the aromatic substituent on the (4R)-hydroxyproline moiety. Inhibitors meeting the potency criteria in the cell-based assay and with improved oral bioavailability in rats were identified. BILN 2061 was selected as the best compound, the first NS3 protease inhibitor reported with antiviral activity in man.

  DOI：

  10.1021/jm0342414